Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $12 Price Target
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $8 Price Target
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.
Avid Bioservices Analyst Ratings
RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $8
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Analysts' Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
No Data
No Data